American Society of Retina Specialists Meeting

The American Society of Retina Specialists meeting in San Diego included the latest clinical research on retinal diseases.

Ohr Pharmaceuticals reported additional interim data from its phase 2 study on Squalamine eye drops for the treatment of wet age-related macular degeneration.

At the American Society of Retina Specialists meeting in San Diego, Rahul N. Khurana, MD, discusses a subgroup analysis of AMD with pigment epithelial detachment.

SAN DIEGO — A handheld ETDRS device may offer benefits of convenience and portability, as well as the ability to assess ETDRS visual acuity without a dedicated testing lane, according to a speaker here.

SAN DIEGO — Abicipar pegol, an engineered DARPin protein, shows promise for maintaining treatment gains at longer treatment intervals in patients with age-related macular degeneration, according to a speaker here.

SAN DIEGO — Incidence of mortality and morbidity was significantly increased among patients with extraocular cytomegalovirus disease, according to a poster presented at the American Society of Retina Specialists annual meeting.

SAN DIEGO — Signs of early or late age-related macular degeneration were present in the vast majority of contralateral eyes of patients enrolled in the VIEW 1 and VIEW 2 studies, according to a poster presented at the American Society of Retina Specialists annual meeting.

SAN DIEGO — Visual acuity gains achieved during the first year of treatment with ranibizumab and prompt or deferred laser in patients with diabetic macular edema are maintained through 5 years, with minimal further treatment needed after 3 years, according to a speaker here.

SAN DIEGO — Baseline visual acuity and features of the outer retina seen on spectral-domain optical coherence tomography can help predict final visual outcome in patients with macular edema secondary to retinal vein occlusion, according to a speaker here.

SAN DIEGO — Optimal treatment for 65% of AREDS 2 study patients is something other than the AREDS formulation, Carl C. Awh, MD, told colleagues at the American Society of Retina Specialists annual meeting.